Ociperlimab

欧司珀利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameOciperlimab
Drug Alias NameBGB-A1217WCD-118
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[24] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeigene Guangzhou Biologics Manufacturing Co LtdNovartis Pharma AgBeOne Medicines Ltd +[6] 
Inactive CompaniesFudan University
Active IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[11] 
Inactive IndicationsCholangiocarcinoma

Other Information

ATC CodeN/A
Related LinksN/A